{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:48:42Z","timestamp":1781534922251,"version":"3.54.5"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s10741-018-09768-9","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T04:21:47Z","timestamp":1558671707000},"page":"421-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Cardiorenal syndrome in heart failure with preserved ejection fraction\u2014an under-recognized clinical entity"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0718-7416","authenticated-orcid":false,"given":"Akanksha","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napatt","family":"Kanjanahattakij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Rangaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"issue":"6","key":"9768_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","volume":"31","author":"C Ronco","year":"2010","unstructured":"Ronco C, MCullough P, Anker SD et al (2010) Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31(6):703\u2013711","journal-title":"Eur Heart J"},{"issue":"5","key":"9768_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0735-1097(02)02955-8","volume":"41","author":"PA McCullough","year":"2003","unstructured":"McCullough PA (2003) Why is chronic kidney disease the \u201cspoiler\u201d for cardiovascular outcomes? J Am Coll Cardiol 41(5):725\u2013728","journal-title":"J Am Coll Cardiol"},{"key":"9768_CR3","unstructured":"NHLBI Working Group. Cardio-renal connections in heart failure and cardiovascular disease. National Heart, Lung, and Blood Institute Web site. \n                    http:\/\/www.nhlbi.nih.gov\/meetings\/workshops\/cardiorenal-hf-hd.htm\n                    \n                  . Accessed 20 October 2017"},{"issue":"6","key":"9768_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","volume":"113","author":"VL Roger","year":"2013","unstructured":"Roger VL (2013) Epidemiology of heart failure. Circ Res 113(6):646\u2013659","journal-title":"Circ Res"},{"key":"9768_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14:591\u2013602","journal-title":"Nat Rev Cardiol"},{"key":"9768_CR6","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1161\/CIRCULATIONAHA.109.886473","volume":"121","author":"JS Bock","year":"2010","unstructured":"Bock JS, Gottlieb SS (2010) Cardiorenal syndrome: new perspectives. Circulation 121:2592\u20132600","journal-title":"Circulation"},{"key":"9768_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jacc.2003.07.031","volume":"43","author":"DE Forman","year":"2004","unstructured":"Forman DE, Butler J, Wang Y, Abraham WT, O\u2019Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM (2004) Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43:61\u201367","journal-title":"J Am Coll Cardiol"},{"key":"9768_CR8","doi-asserted-by":"crossref","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179\u2013c184","DOI":"10.1159\/000339789"},{"key":"9768_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000316038","volume":"116","author":"JM Testani","year":"2010","unstructured":"Testani JM, McCauley BD, Chen J, Shumski M, Shannon RP (2010a) Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions. Cardiology 116:206\u2013212","journal-title":"Cardiology"},{"issue":"2","key":"9768_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","volume":"149","author":"KF Adams","year":"2005","unstructured":"Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209\u2013216","journal-title":"Am Heart J"},{"issue":"48","key":"9768_CR11","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1093\/eurheartj\/ehu320","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Tang WH, Testani JM, McMurray JJ (2014a) Terminology and definition of changes renal function in heart failure. Eur Heart J 35(48):3413\u20133416","journal-title":"Eur Heart J"},{"issue":"4","key":"9768_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0195-668X(02)00428-1","volume":"24","author":"M Fischer","year":"2003","unstructured":"Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, D\u00f6ring A, Broeckel U, Riegger G, Schunkert H (2003) Prevalence of left ventricular diastolic dysfunction in the community: results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 24(4):320\u2013328","journal-title":"Eur Heart J"},{"issue":"5","key":"9768_CR13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1161\/01.CIR.0000048123.22359.A0","volume":"107","author":"M Kawaguchi","year":"2003","unstructured":"Kawaguchi M, Hay I, Fetics B, Kass DA (2003) Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107(5):714\u2013720","journal-title":"Circulation"},{"issue":"8","key":"9768_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","volume":"5","author":"FH Messerli","year":"2017","unstructured":"Messerli FH, Rimoldi SF, Bangalore S (2017) The transition from hypertension to heart failure: contemporary update. JACC Heart Fail. 5(8):543\u2013551","journal-title":"JACC Heart Fail."},{"key":"9768_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1113\/jphysiol.1931.sp002761","volume":"72","author":"FR Winton","year":"1931","unstructured":"Winton FR (1931) The influence of venous pressure on the isolated mammalian kidney. J Physiol 72:49\u201361","journal-title":"J Physiol"},{"issue":"6","key":"9768_CR16","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1097\/00005373-199912000-00002","volume":"47","author":"JM Doty","year":"1999","unstructured":"Doty JM, Saggi BH, Sugerman HJ, Blocher CR, Pin R, Fakhry I, Gehr TWB, Sica DA (1999) Effect of increased renal venous pressure on renal function. J Trauma 47(6):1000\u20131003","journal-title":"J Trauma"},{"issue":"23","key":"9768_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/eurheartj\/ehv010","volume":"36","author":"K Damman","year":"2015","unstructured":"Damman K, Testani JM (2015) The kidney in heart failure: an update. Eur Heart J 36(23):1437\u20131444","journal-title":"Eur Heart J"},{"issue":"7","key":"9768_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","volume":"53","author":"W Mullens","year":"2009","unstructured":"Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53(7):589\u2013596","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"9768_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","volume":"53","author":"K Damman","year":"2009","unstructured":"Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53(7):582\u2013588","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"9768_CR20","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1001\/jama.294.13.1625","volume":"294","author":"C Binanay","year":"2005","unstructured":"Binanay C, Califf RM, Hasselblad V, O\u2019Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW, ESCAPE Investigators and ESCAPE Study Coordinators (2005) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294(13):1625\u20131633","journal-title":"JAMA"},{"issue":"8","key":"9768_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jchf.2016.03.016","volume":"4","author":"N Iida","year":"2016","unstructured":"Iida N, Seo Y, Sai S, Machino-Ohtsuka T, Yamamoto M, Ishizu T, Kawakami Y, Aonuma K (2016) Clinical implications of intrarenal hemodynamic evaluation by Doppler ultrasonography in heart failure. JACC Heart Failure 4(8):674\u2013682","journal-title":"JACC Heart Failure"},{"issue":"9","key":"9768_CR22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jchf.2017.05.006","volume":"5","author":"P Nijst","year":"2017","unstructured":"Nijst P, Martens P, Dupont M, Tang WHW, Mullens W (2017) Intrarenal flow alterations during transition from euvolemia to intravascular volume expansion in heart failure patients. JACC Heart Fail. 5(9):672\u2013681","journal-title":"JACC Heart Fail."},{"issue":"6","key":"9768_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2013.04.070","volume":"62","author":"FH Verbrugge","year":"2013","unstructured":"Verbrugge FH, Dupont M, Steels P, Grieten L, Malbrain M, Tang WHW, Mullens W (2013) Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 62(6):485\u2013495","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"9768_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jacc.2007.09.043","volume":"51","author":"W Mullens","year":"2008","unstructured":"Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, Paganini E, Tang WHW (2008a) Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 51(3):300\u2013306","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"9768_CR25","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.cardfail.2008.02.010","volume":"14","author":"W Mullens","year":"2008","unstructured":"Mullens W, Abrahams Z, Francis GS, Taylor DO, Starling RC, Tang WHW (2008b) Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail 14(6):508\u2013514","journal-title":"J Card Fail"},{"issue":"13","key":"9768_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","volume":"53","author":"CSP Lam","year":"2009","unstructured":"Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community- based study. J Am Coll Cardiol 53(13):1119\u20131126","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"9768_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/CIRCHEARTFAILURE.110.958801","volume":"4","author":"T Thenappan","year":"2011","unstructured":"Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, Rich S (2011) Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 4(3):257\u2013265","journal-title":"Circ Heart Fail"},{"key":"9768_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0735-1097(00)01102-5","volume":"37","author":"S Ghio","year":"2001","unstructured":"Ghio S, Campana C, Inserra C et al (2001) Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37:183\u2013188","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"9768_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1751-7133.2011.00275.x","volume":"18","author":"LM Mielniczuk","year":"2012","unstructured":"Mielniczuk LM, Chandy G, Stewart D, Dominguez VC, Haddad H, Pugliese C, Davies RA (2012) Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure. Congestive Heart Failure 18(3):151\u2013157","journal-title":"Congestive Heart Failure"},{"issue":"2","key":"9768_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.amjcard.2017.04.019","volume":"120","author":"M Mukherjee","year":"2017","unstructured":"Mukherjee M, Sharma K, Madrazo JA, Tedford RJ, Russell SD, Hays AG (2017) Right-sided cardiac dysfunction in heart failure with preserved ejection fraction and worsening renal function. Am J Cardiol 120(2):274\u2013278","journal-title":"Am J Cardiol"},{"issue":"1","key":"9768_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1086\/690018","volume":"7","author":"NP Nickel","year":"2017","unstructured":"Nickel NP, O\u2019Leary JM, Brittain EL (2017) Kidney dysfunction in patients with pulmonary arterial hypertension. Pulmonary Circulation 7(1):38\u201354","journal-title":"Pulmonary Circulation"},{"issue":"4","key":"9768_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263\u2013271","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"9768_CR33","doi-asserted-by":"publisher","first-page":"R1449","DOI":"10.1152\/ajpregu.00440.2010","volume":"299","author":"M Damkj\u00e6r","year":"2010","unstructured":"Damkj\u00e6r M, Vafaee M, M\u00f8ller ML, Braad PE, Petersen H, H\u00f8ilund-Carlsen PF, Bie P (2010) Renal cortical and medullary blood flow responses to altered NO availability in humans. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 299(6):R1449\u2013R1455","journal-title":"American Journal of Physiology. Regulatory, Integrative and Comparative Physiology"},{"key":"9768_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6871081","volume":"2017","author":"N Satoh","year":"2017","unstructured":"Satoh N, Nakamura M, Suzuki A, Tsukada H et al (2017) Effects of nitric oxide on renal proximal tubular Na+ transport. Biomed Res Int 2017:6871081","journal-title":"Biomed Res Int"},{"key":"9768_CR35","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","volume":"39","author":"SJ Shah","year":"2018","unstructured":"Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, Beussink-Nelson L, Ljung Fax\u00e9n U, Fermer ML, Broberg MA, Gan LM, Lund LH (2018) Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 39:3439\u20133450","journal-title":"Eur Heart J"},{"key":"9768_CR36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/ehjcvp\/pvv008","volume":"1","author":"S Paolillo","year":"2015","unstructured":"Paolillo S, Filardi PP (2015) Cardio-renal protection through renin-angiotensin-aldosterone system inhibition: current knowledge and new perspectives. European Heart Journal-Cardiovascular Pharmacotherapy 1:132\u2013133","journal-title":"European Heart Journal-Cardiovascular Pharmacotherapy"},{"key":"9768_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"The Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","unstructured":"The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting\u2013enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145\u2013153","journal-title":"N Engl J Med"},{"key":"9768_CR38","doi-asserted-by":"crossref","unstructured":"Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782\u2013788","DOI":"10.1016\/S0140-6736(03)14286-9"},{"key":"9768_CR39","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa042739","volume":"351","author":"The PEACE Trial Investigators","year":"2004","unstructured":"The PEACE Trial Investigators (2004) Angiotensin-converting\u2013enzyme inhibition in stable coronary artery disease. N Engl J Med 351:2058\u20132068","journal-title":"N Engl J Med"},{"key":"9768_CR40","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/01.HYP.0000039506.43589.D5","volume":"40","author":"A Tojo","year":"2002","unstructured":"Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T (2002) Angiotensin II and oxidative stress in Dahl salt-sensitive rat with heart failure. Hypertension 40:834\u2013839","journal-title":"Hypertension"},{"issue":"5","key":"9768_CR41","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ajh\/hps100","volume":"26","author":"M Ravera","year":"2013","unstructured":"Ravera M, Noberasco G, Signori A, Re M, Filippi A, Cannavo R, Weiss U, Cricelli C, Deferrari G, Paoletti E (2013) Left-ventricular hypertrophy and renal outcome in hypertensive patients in primary-care. Am J Hypertens 26(5):700\u2013707","journal-title":"Am J Hypertens"},{"issue":"2","key":"9768_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2016.11.022","volume":"70","author":"LR Zelnick","year":"2017","unstructured":"Zelnick LR, Katz R, Young BA, Correa A, Kestenbaum BR, de Boer IH, Bansal N (2017) Echocardiographic measures and estimated GFR decline among African Americans: the Jackson Heart Study. Am J Kidney Dis 70(2):199\u2013206","journal-title":"Am J Kidney Dis"},{"key":"9768_CR43","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.cardfail.2016.02.012","volume":"22","author":"M Cameli","year":"2016","unstructured":"Cameli M, Mondillo S, Righini FM, Lisi M, Dokollari A, Lindqvist P, Maccherini M, Henein M (2016) Left ventricular deformation and myocardial fibrosis in patients with advanced heart failure requiring transplantation. J Card Fail 22:901\u2013907","journal-title":"J Card Fail"},{"issue":"5","key":"9768_CR44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","volume":"63","author":"E Kraigher-Krainer","year":"2014","unstructured":"Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, McMurray JJV, Solomon SD (2014) Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 63(5):447\u2013456","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"9768_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-017-0615-6","volume":"16","author":"A Natali","year":"2017","unstructured":"Natali A, Nesti L, Fabiani I, Calogero E, Di Bello V (2017) Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Diabetol 16(1):130","journal-title":"Cardiovasc Diabetol"},{"issue":"38","key":"9768_CR46","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ et al (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585\u20132594","journal-title":"Eur Heart J"},{"issue":"20","key":"9768_CR47","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","volume":"114","author":"BA Borlaug","year":"2006","unstructured":"Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA (2006) Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114(20):2138\u20132147","journal-title":"Circulation"},{"issue":"7","key":"9768_CR48","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.amjcard.2015.06.038","volume":"116","author":"DA Klein","year":"2015","unstructured":"Klein DA, Katz DH, Beussink-Nelson L, Sanchez CL, Strzelczyk TA, Shah SJ (2015) Association of chronic kidney disease with chronotropic incompetence in heart failure with preserved ejection fraction. Am J Cardiol 116(7):1093\u20131100","journal-title":"Am J Cardiol"},{"key":"9768_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1152\/physrev.1997.77.1.75","volume":"77","author":"GF DiBona","year":"1997","unstructured":"DiBona GF, Kopp UC (1997) Neural control of renal function. Physiol Rev 77:75\u2013197","journal-title":"Physiol Rev"},{"issue":"9","key":"9768_CR50","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1681\/ASN.2014010093","volume":"26","author":"C Drechsler","year":"2015","unstructured":"Drechsler C, Delgado G, Wanner C, Blouin K, Pilz S, Tomaschitz A, Kleber ME, Dressel A, Willmes C, Krane V, Kramer BK, Marz W, Ritz E, van Gilst WH, van der Harst P, de Boer RA (2015) Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies. J Am Soc Nephrol 26(9):2213\u20132221","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"9768_CR51","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfq770","volume":"26","author":"G Wagener","year":"2011","unstructured":"Wagener G, Minhaz M, Mattis FA, Kim M, Emond JC, Lee HT (2011) Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transplant 26(5):1717\u20131723","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"9768_CR52","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/j.ajkd.2009.07.020","volume":"54","author":"M Haase","year":"2009","unstructured":"Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A (2009) Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 54(6):1012\u20131024","journal-title":"American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation"},{"key":"9768_CR53","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1161\/CIRCULATIONAHA.117.030112","volume":"137","author":"T Ahmad","year":"2018","unstructured":"Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, Felker GM, Hernandez AF, O\u2019Connor CM, Sabbisetti VS, Bonventre JV, Wilson FP, Coca SG, Testani JM (2018) Worsening renal function in acute heart failure patients undergoing aggressive diuresis is not associated with tubular injury. Circulation 137:2016\u20132028. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030112","journal-title":"Circulation"},{"issue":"6","key":"9768_CR54","first-page":"453","volume":"4","author":"WL Miller","year":"2016","unstructured":"Miller WL, Mullan BP (2016) Volume overload profiles in patients with preserved and reduced ejection fraction chronic heart failure: are there differences? A pilot study. JACC: Heart Failure 4(6):453\u2013459","journal-title":"JACC: Heart Failure"},{"issue":"3","key":"9768_CR55","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCHEARTFAILURE.114.001734","volume":"8","author":"M Takei","year":"2015","unstructured":"Takei M, Kohsaka S, Shiraishi Y, Goda A, Izumi Y, Yagawa M, Mizuno A, Sawano M, Inohara T, Kohno T, Fukuda K, Yoshikawa T (2015) Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction. Circ Heart Fail. 8(3):527\u2013532","journal-title":"Circ Heart Fail."},{"issue":"10","key":"9768_CR56","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jchf.2018.04.008","volume":"6","author":"K Sharma","year":"2018","unstructured":"Sharma K, Vaishnav J, Kalathiya R, Hu JR, Miller J, Shah N, Hill T, Sharp M, Tsao A, Alexander KM, Gupta R, Montemayor K, Kovell L, Chasler JE, Lee YJ, Fine DM, Kass DA, Weiss RG, Thiemann DR, Ndumele CE, Schulman SP, Russell SD (2018) Randomized evaluation of heart failure with preserved ejection fraction patients with acute heart failure and dopamine: the ROPA-DOP Trial. JACC Heart Fail 6(10):859\u2013870","journal-title":"JACC Heart Fail"},{"issue":"16","key":"9768_CR57","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147\u2013e239","journal-title":"J Am Coll Cardiol"},{"key":"9768_CR58","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009149","volume":"7","author":"MA Brisco-Bacik","year":"2018","unstructured":"Brisco-Bacik MA, ter Maaten JM, Houser SR, Vedage NA et al (2018) Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc 7:e009149","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"9768_CR59","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.109.933275","volume":"122","author":"JM Testani","year":"2010","unstructured":"Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP (2010b) Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122(3):265\u2013272","journal-title":"Circulation"},{"issue":"9","key":"9768_CR60","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364(9):797\u2013805","journal-title":"N Engl J Med"},{"issue":"11","key":"9768_CR61","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.jacc.2005.05.098","volume":"46","author":"BA Bart","year":"2005","unstructured":"Bart BA, Boyle A, Bank AJ, Anand I, Olivari MT, Kraemer M, Mackedanz S, Sobotka PA, Schollmeyer M, Goldsmith SR (2005) Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients with Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 46(11):2043\u20132046","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"9768_CR62","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jacc.2006.07.073","volume":"49","author":"MR Costanzo","year":"2007","unstructured":"Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49(6):675\u2013683","journal-title":"J Am Coll Cardiol"},{"key":"9768_CR63","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","volume":"367","author":"BA Bart","year":"2012","unstructured":"Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367:2296\u20132304","journal-title":"N Engl J Med"},{"key":"9768_CR64","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456\u20132467","journal-title":"N Engl J Med"},{"issue":"11","key":"9768_CR65","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jacc.2014.01.087","volume":"64","author":"K Damman","year":"2014","unstructured":"Damman K, Perez AC, Anand IS, Komajda M, McKelvie RS, Zile MR, Massie B, Carson PE, McMurray JJV (2014b) Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol 64(11):1106\u20131113","journal-title":"J Am Coll Cardiol"},{"key":"9768_CR66","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392","journal-title":"N Engl J Med"},{"key":"9768_CR67","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003588","volume":"10","author":"IE Beldhuis","year":"2017","unstructured":"Beldhuis IE, Streng KW, Maaten JMT et al (2017) Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction. Circ Heart Fail 10:e003588","journal-title":"Circ Heart Fail"},{"key":"9768_CR68","doi-asserted-by":"crossref","unstructured":"Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012; 59:442\u2013451, Effects of Vasodilation in Heart Failure With Preserved or Reduced Ejection Fraction","DOI":"10.1016\/j.jacc.2011.09.062"},{"issue":"8","key":"9768_CR69","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0002-9343(00)00601-X","volume":"109","author":"EF Philbin","year":"2000","unstructured":"Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL (2000) Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 109(8):605\u2013613","journal-title":"Am J Med"},{"issue":"9386","key":"9768_CR70","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (London, England) 362(9386):777\u2013781","journal-title":"Lancet (London, England)"},{"issue":"5","key":"9768_CR71","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.amjcard.2007.10.026","volume":"101","author":"C Tribouilloy","year":"2008","unstructured":"Tribouilloy C, Rusinaru D, Leborgne L, Peltier M, Massy Z, Slama M (2008) Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol 101(5):639\u2013644","journal-title":"Am J Cardiol"},{"issue":"20","key":"9768_CR72","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2012.14785","volume":"308","author":"LH Lund","year":"2012","unstructured":"Lund LH, Benson L, Dahlstrom U, Edner M (2012) Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308(20):2108\u20132117","journal-title":"JAMA"},{"issue":"10","key":"9768_CR73","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/eurjhf\/hfs101","volume":"14","author":"K Patel","year":"2012","unstructured":"Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A (2012) Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail 14(10):1179\u20131188","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"9768_CR74","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/ejhf.609","volume":"18","author":"K Damman","year":"2016","unstructured":"Damman K, Solomon SD, Pfeffer MA, Swedberg K, Yusuf S, Young JB, Rouleau JL, Granger CB, McMurray JJV (2016) Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. Eur J Heart Fail 18(12):1508\u20131517","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"9768_CR75","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.232","volume":"17","author":"AA Voors","year":"2015","unstructured":"Voors AA, Gori M, Liu LC, Claggett B et al (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 17(5):510\u2013517","journal-title":"Eur J Heart Fail"},{"key":"9768_CR76","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"issue":"7","key":"9768_CR77","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","volume":"5","author":"SD Solomon","year":"2017","unstructured":"Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV (2017) Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF Trial. JACC Heart Fail. 5(7):471\u2013482","journal-title":"JACC Heart Fail."},{"issue":"17","key":"9768_CR78","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Y Lytvyn","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI (2017) Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Send to Circulation 136(17):1643\u20131658","journal-title":"Send to Circulation"},{"issue":"5","key":"9768_CR79","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Prato SD, Chilton R, RA DF (2016) SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care 39(5):717\u2013725","journal-title":"Diabetes Care"},{"issue":"7","key":"9768_CR80","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"2","key":"9768_CR81","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B (2018) Empagiflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137(2):119\u2013129","journal-title":"Circulation"},{"key":"9768_CR82","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB (2016a) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322","journal-title":"N Engl J Med"},{"key":"9768_CR83","doi-asserted-by":"crossref","unstructured":"Verma S, Leiter LA, Meizer CD, et al (2018) Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use: results from the LEADER trial. Circulation 138(15):1605\u20131607","DOI":"10.1161\/CIRCULATIONAHA.118.036862"},{"key":"9768_CR84","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T (2016b) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844","journal-title":"N Engl J Med"},{"key":"9768_CR85","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, \u00d6hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377:1228\u20131239","journal-title":"N Engl J Med"},{"issue":"22","key":"9768_CR86","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1111\/bph.13686","volume":"174","author":"G Esposito","year":"2017","unstructured":"Esposito G, Cappetta D, Russo R, Rivellino A, Ciuffreda LP, Roviezzo F, Piegari E, Berrino L, Rossi F, De Angelis A, Urbanek K (2017) Sitagliptan reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. Br J Pharmacol 174(22):4070\u20134086","journal-title":"Br J Pharmacol"},{"issue":"9766","key":"9768_CR87","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","volume":"377","author":"WT Abraham","year":"2011","unstructured":"Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377(9766):658\u2013666","journal-title":"Lancet"},{"issue":"1","key":"9768_CR88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/1755-5922.12231","volume":"35","author":"RK Ghosh","year":"2017","unstructured":"Ghosh RK, Banerjee K, Tummala R, Ball S, Ravakhah K, Gupta A (2017) Serelaxin in acute heart failure: most recent update on clinical and preclinical evidence. Cardiovasc Ther 35(1):55\u201363","journal-title":"Cardiovasc Ther"},{"issue":"16","key":"9768_CR89","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/eurheartj\/eht497","volume":"35","author":"G Filippatos","year":"2014","unstructured":"Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua T, Ponikowski P, Severin T, Unemori E, Voors AA, Metra M (2014) Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 35(16):1041\u20131050","journal-title":"Eur Heart J"},{"key":"9768_CR90","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Lewis GD, Shah SJ, LeWinter M, Semigran M, Davila-Roman VG, Anstrom K, Hernandez A, Braunwald E, Redfield MM, Borlaug BA (2017) INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction): rationale and design. Circ Heart Fail 10:e003862","DOI":"10.1161\/CIRCHEARTFAILURE.117.003862"},{"issue":"4","key":"9768_CR91","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1161\/CIRCULATIONAHA.114.012957","volume":"131","author":"P Zamani","year":"2015","unstructured":"Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, Ischiropoulos H, Townsend RR, Margulies KB, Cappola TP, Poole DC, Chirinos JA (2015) Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 131(4):371\u2013380","journal-title":"Circulation"},{"key":"9768_CR92","unstructured":"Borlaug BA 2018 INDIE-HFpEF: Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF. A randomized clinical trial. Paper Presented to The American College of Cardiology (ACC) Annual Scientific Session Orlando, 2018"},{"key":"9768_CR93","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/164_2016_100","volume":"243","author":"S Breitenstein","year":"2017","unstructured":"Breitenstein S, Roessig L, Sander P, Lewis KS (2017) Novel sGC stimulators and sGC activators for the treatment of heart failure. Handb Exp Pharmacol 243:225\u2013247","journal-title":"Handb Exp Pharmacol"},{"issue":"15","key":"9768_CR94","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Gheorghiade M (2017) Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 38(15):1119\u20131127","journal-title":"Eur Heart J"},{"issue":"23\u201324","key":"9768_CR95","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00508-016-1068-8","volume":"128","author":"J Mascherbauer","year":"2016","unstructured":"Mascherbauer J, Gr\u00fcnig E, Halank M, Hohenforst-Schmidt W, Kammerlander AA, Pretsch I, Steringer-Mascherbauer R, Ulrich S, Lang IM, Wargenau M, Frey R, Bonderman D (2016) Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: study protocol for a randomized controlled trial. Wien Klin Wochenschr 128(23\u201324):882\u2013889","journal-title":"Wien Klin Wochenschr"},{"key":"9768_CR96","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.117.032094","volume":"137","author":"T Feldman","year":"2018","unstructured":"Feldman T, Mauri L, Kahwash R, Litwin S, Ricciardi MJ, van der Harst P, Penicka M, Fail PS, Kaye DM, Petrie MC, Basuray A, Hummel SL, Forde-McLean R, Nielsen CD, Lilly S, Massaro JM, Burkhoff D, Shah SJ (2018) Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure with Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With heart Failure]). A phase 2, randomized, sham-controlled trial. Circulation 137:364\u2013375","journal-title":"Circulation"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-09768-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-018-09768-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-09768-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T23:07:37Z","timestamp":1590188857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-018-09768-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["9768"],"URL":"https:\/\/doi.org\/10.1007\/s10741-018-09768-9","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]},"assertion":[{"value":"24 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}